Abigail Brooks, MA

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.

Participants given omadacycline had high fecal concentrations with a distinct microbiome profile compared to those in the vancomycin group, with study results calling attention to the importance of antibiotics’ impact on the gut microbiome.

Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.

Although no differences were observed in the safety and efficacy of FDA-approved combination DAA therapies, female participants reported numerically more adverse events than male participants.

Topline data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile infection (CDI) vaccine.

Just 8.5% of eligible patients were screened for hepatitis C, and among them, 5.9% tested positive for HCV antibody and 3.0% had an active infection.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Tatyana Kushner, MD, MSCE, offers her insights on the Biden administration's hepatitis C elimination plan.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

Interaction with providers increased testing but did not translate to treatment initiation.

This class of medications were associated with a greater risk of Clostridioides difficile infection (CDI).

Patients treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin; although there were no significant differences observed in the global or clinical cure rate between the 2 treatments.

A new study found a higher risk of CDI associated with clindamycin and lower risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.